Advanced Biomed Inc is a holding company incorporated in the State of Nevada that operates through subsidiaries in Taiwan and Hong Kong, focusing on the integration of semiconductor technology and biotechnology to develop microfluidic technology platforms for cancer detection.
The company generates revenue through the development and planned commercialization of medical testing equipment and related products, including microfluidic biochips, immunostaining kits, and devices…
Advanced Biomed Inc is a holding company incorporated in the State of Nevada that operates through subsidiaries in Taiwan and Hong Kong, focusing on the integration of semiconductor technology and biotechnology to develop microfluidic technology platforms for cancer detection.
The company generates revenue through the development and planned commercialization of medical testing equipment and related products, including microfluidic biochips, immunostaining kits, and devices such as A+Pre, AC-1000, A+CellScan, A+SCDrop, and A+LCGuard, targeting healthcare providers and research institutions for cancer screening and diagnosis.
The company operates through the following segments: Advanced Biomed Taiwan and Advanced Biomed HK.
- Advanced Biomed Taiwan is responsible for the main operation and the design and development of the company’s primary technologies and products.
- Advanced Biomed HK is mainly responsible for market operation and management in China, localized production, product registration, and future local market sales of the company’s products in accordance with relevant local regulations in China.
Advanced Biomed Inc positions itself as an innovator in the oncology detection market by leveraging its proprietary microfluidic technology platform and antigen-independent rare cell enrichment system, which offers advantages over conventional antibody-based methods in terms of cost, processing time, and ability to detect circulating tumor cells with low antigen expression.
The company serves hospitals, clinical laboratories, and research institutions, particularly in China, with plans to expand to North American and European markets through localized subsidiaries to meet regional regulatory requirements.